SCHEMBL17680010

SCHEMBL17680010

c1ccc(-c2ccc(-c3c4ccccc4c(-c4ccc(-c5cccc6ccccc56)nc4)c4ccccc34)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.43
CYP11B2 P19099 3/20 0.43
ATR Q13535 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
MAPK1 P28482 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TNF P01375 1/20 0.41
ENPP3 O14638 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12436888 1.00 CYP11B1 (0.43) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL12435976 0.98 CYP11B1 (0.44) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL21467566 0.96 TNF (0.44) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL12435751 0.93 CA12 (0.41) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL17680015 0.93 CYP11B1 (0.41) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL12014660 0.91 LMNA (0.41) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL12435753 0.91 TNF (0.42) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL23094374 0.91 MEN1 (0.39) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL21249206 0.91 CA12 (0.40) CYP11B1CYP11B2ATRKDM4EALDH1A1
SCHEMBL12435750 0.91 CYP11B1 (0.45) CYP11B1CYP11B2ATRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190319194-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2019-10-17 US disclosed
US-10381569-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2019-08-13 US disclosed
US-20160149139-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2016-05-26 US disclosed
US-20160149139-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2016-05-26 US disclosed
US-20160104847-A1 NOVEL COMPOUNDS AND USES IN DEVICES UNIVERSAL DISPLAY CORPORATION 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160104847-A1 NOVEL COMPOUNDS AND USES IN DEVICES TERT, UACA, TXN CYP11B1 4245/4885CYP11B2 3918/4885ATR 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.